Novel Combination Therapy for Triple-Negative Breast Cancer based on an Intelligent Hollow Carbon Sphere

Author:

Yin Yue12,Yan Yaping3,Fan Biao2,Huang Wenping24,Zhang Jie24,Hu Hai-Yan5,Li Xiaoqiong6,Xiong Dongbin7,Chou Shu-Lei5,Xiao Yao58,Wang Hai24

Affiliation:

1. School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.

2. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.

3. College of Materials Engineering, Henan University of Engineering, Xinzheng 451191, China.

4. University of Chinese Academy of Sciences, Beijing 100049, China.

5. Institute for Carbon Neutralization, College of Chemistry and Materials Engineering, Wenzhou University, Wenzhou 325035, China.

6. School of Life Science, Beijing Institute of Technology, Beijing 100081, China.

7. Institute of Advanced Materials, Hubei Normal University, Huangshi 415000, China.

8. State Key Laboratory of Electrical Insulation and Power Equipment, School of Electrical Engineering, Xi’an Jiaotong University, Xi’an, Shaanxi, China.

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer with high mortality, and the efficacy of monotherapy for TNBC is still disappointing. Here, we developed a novel combination therapy for TNBC based on a multifunctional nanohollow carbon sphere. This intelligent material contains a superadsorbed silicon dioxide sphere, sufficient loading space, a nanoscale hole on its surface, a robust shell, and an outer bilayer, and it could load both programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) small-molecule immune checkpoints and small-molecule photosensitizers with excellent loading contents, protect these small molecules during the systemic circulation, and achieve accumulation of them in tumor sites after systemic administration followed by the application of laser irradiation, thereby realizing dual attack of photodynamic therapy and immunotherapy on tumors. Importantly, we integrated the fasting-mimicking diet condition that can further enhance the cellular uptake efficiency of nanoparticles in tumor cells and amplify the immune responses, further enhancing the therapeutic effect. Thus, a novel combination therapy “PD-1/PD-L1 immune checkpoint blockade + photodynamic therapy + fasting-mimicking diet”was developed with the aid of our materials, which eventually achieved a marked therapeutic effect in 4T1-tumor-bearing mice. The concept can also be applied to the clinical treatment of human TNBC with guiding significance in the future.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference46 articles.

1. Risk factors for triple-negative breast cancer in women under age 45;Dolle JM;Cancer Epidemiol Biomark Prev,2009

2. Immunotherapy for triple-negative breast cancer;Cao Y;Pharmaceutics,2021

3. Metastatic and triple-negative breast cancer: Challenges and treatment options;Al-Mahmood S;Drug Deliv Transl Res,2018

4. Triple negative breast cancer: Pitfalls and progress;Zagami P;NPJ Breast Cancer,2022

5. Estrogens and progestogens in triple negative breast cancer: Do they harm?;Barele M;Cancers,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3